Amedeo Smart

Free Medical Literature Service

 

Amedeo

Anemia
  Free Subscription

Articles published in
JAMA
    February 2023
  1. HARRIS E
    FDA Approves First Oral Treatment for Kidney Disease-Induced Anemia.
    JAMA. 2023 Feb 15. doi: 10.1001/jama.2023.1556.
    >> Share

  2. LARKIN HD
    Sickle Cell Disease Gene Therapy Trial Paused.
    JAMA. 2023;329:364.
    >> Share

    November 2022
  3. VLACHADIS N, Vrachnis N
    A Review of Sickle Cell Disease.
    JAMA. 2022;328:1979.
    >> Share

  4. KAVANAGH PL, Fasipe T, Wun T
    A Review of Sickle Cell Disease-Reply.
    JAMA. 2022;328:1979-1980.
    >> Share

  5. LARKIN HD
    Gene Therapy for Sickle Cell Disease, beta-Thalassemia Enters Regulatory Reviews.
    JAMA. 2022;328:1798.
    >> Share

    October 2022
  6. KUEHN BM
    Children With Sickle Cell Anemia Not Receiving Recommended Care.
    JAMA. 2022;328:1583-1584.
    >> Share

    September 2022
  7. RUBIN R
    New Gene Therapy for beta-Thalassemia.
    JAMA. 2022;328:1030.
    >> Share

    August 2022
  8. SLOMSKI A
    Sickle Cell Trait Associated With Kidney Failure and COVID-19 Death.
    JAMA. 2022;328:415.
    >> Share

    July 2022
  9. KAVANAGH PL, Fasipe TA, Wun T
    Sickle Cell Disease: A Review.
    JAMA. 2022;328:57-68.
    >> Share

    June 2022
  10. OSHIMA T, Kinjo K, Kinjo M
    Chronic Abdominal Pain and Anemia in a 59-Year-Old Man.
    JAMA. 2022 Jun 24. pii: 2793812. doi: 10.1001/jama.2022.9194.
    >> Share

    February 2022
  11. SLOMSKI A
    Oral Daprodustat Treats Anemia in Chronic Kidney Disease.
    JAMA. 2022;327:710.
    >> Share

    October 2021
  12. ABOU BAKER NM, Davis AM
    Gastrointestinal Evaluation of Iron Deficiency Anemia.
    JAMA. 2021;326:1624-1625.
    >> Share

    September 2021
  13. KENTER MJH, Cohen AF
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    JAMA. 2021;326:974-975.
    >> Share

  14. GURKAN UA
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease.
    JAMA. 2021;326:975.
    >> Share

  15. CASELLA JF, Kronsberg SS, Gorney RT
    Poloxamer 188 vs Placebo for Painful Vaso-occlusive Episodes in Children and Adults With Sickle Cell Disease-Reply.
    JAMA. 2021;326:975-976.
    >> Share

    July 2021
  16. ZHANG H, Kilaru AS, Meisel ZF, Bao Y, et al
    Prescription Drug Monitoring Program Mandates and Opioids Dispensed Following Emergency Department Encounters for Patients With Sickle Cell Disease or Cancer With Bone Metastasis.
    JAMA. 2021;326:274-276.
    >> Share

    June 2021
  17. SATO T, Terada R, Ikeda T
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia.
    JAMA. 2021;325:2505-2506.
    >> Share

  18. DUCROCQ G, Simon T, Steg PG
    Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia-Reply.
    JAMA. 2021;325:2506-2507.
    >> Share

    May 2021

  19. Foreign Letters: London.
    JAMA. 2021;325:1907.
    >> Share

    April 2021
  20. ZYLKE J
    Poloxamer 188 for Sickle Cell Disease.
    JAMA. 2021;325:1524.
    >> Share

  21. CASELLA JF, Barton BA, Kanter J, Black LV, et al
    Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
    JAMA. 2021;325:1513-1523.
    >> Share

  22. EHRENREICH H, Neubauer AP, Miskowiak K
    Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years.
    JAMA. 2021;325:1470-1471.
    >> Share

  23. NATALUCCI G, Bucher HU, Fauchere JC
    Effect of Early Recombinant Human Erythropoietin on Neurodevelopmental Outcomes at Age 5 Years-Reply.
    JAMA. 2021;325:1471-1472.
    >> Share

    February 2021
  24. DUCROCQ G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, et al
    Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial.
    JAMA. 2021;325:552-560.
    >> Share

    January 2021
  25. ABBASI J
    Promising Strategies for Sickle Cell Disease and beta-Thalassemia.
    JAMA. 2021;325:121.
    >> Share

    December 2020
  26. NATALUCCI G, Latal B, Koller B, Ruegger C, et al
    Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.
    JAMA. 2020;324:2324-2327.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016